


To whom it may concern,

The study: "Ilaris® (canakinumab) efficacy and safety in CAPS patients without confirmed mutation on exon 3 of gene CIAS1 and young (<2yrs) CAPS patients with severe neurological (CINCA) phenotype." (EudraCT: 2014-001393-34) never started due to organizational reasons. EOT 31/12/2014.

Yours sincerely,

Prof. dr. C. Wouters

A handwritten signature in blue ink, consisting of a large, sweeping initial 'C' followed by a series of connected loops and a final flourish.